Blog

August 08, 2023 – Everest Pharma is proud to announce the launch of RUXOTOR Cream, a generic version of the FDA-approved OPZELURA (Ruxolitinib Cream 1.5%), offering a significant advancement in the topical treatment of non-segmental vitiligo and mild-to-moderate atopic dermatitis. RUXOTOR Cream contains Ruxolitinib, a Janus kinase (JAK) inhibitor that modulates immune signaling by selectively […]

The U.S. Food and Drug Administration (FDA) approved Opzelura™ (ruxolitinib) cream 1.5% on July 18, 2022, for the topical treatment of nonsegmental vitiligo in adults and pediatric patients aged 12 years and older. Developed by Incyte, Opzelura is the first and only FDA-approved therapy specifically indicated for repigmentation in vitiligo and represents the only topical

August 14, 2023 – Everest Pharma proudly announces the launch of CRAVACIN, the FDA-approved generic version of SOTYKTU, marking a major advancement in the treatment of moderate-to-severe plaque psoriasis. CRAVACIN (Generic SOTYKTU) offers patients a more affordable and accessible alternative to the branded drug, specifically benefiting those managing plaque psoriasis. Deucravacitinib is a TYK2 (tyrosine

Psoriasis affects over 8 million individuals in the United States. The most prevalent form is plaque psoriasis, which impacts 80 to 90 percent of those diagnosed with the condition. This type of psoriasis is marked by inflamed, scaly patches of skin known as “plaques,” which can be itchy and sometimes painful. On lighter skin tones,

June 15, 2024 – Everest Pharma has announced the launch of Resiliva, the world’s first generic version of Resmetirom, marking a significant milestone in the treatment of metabolic and liver diseases. Resiliva is expected to provide an affordable and accessible alternative to the branded medication, particularly for patients suffering from non-alcoholic steatohepatitis (NASH) with liver